Klaus Mohrs

Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds

Armin Hatzelmann, R. Fruchtmann, Klaus Mohrs et al. · Biochemical Pharmacology · 1993 · 78 citations

Pharmacy, Medicinal Chemistry, Pharmacology +8

In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis

R. Fruchtmann, Klaus Mohrs, Armin Hatzelmann et al. · Inflammation Research · 1993 · 47 citations

Medicine, Medicinal Chemistry, Pharmacology +11

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.

R. Müller‐Peddinghaus, C. Kohlsdorfer, Pia Theisen-Popp et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 39 citations

Medicine, Pharmacokinetics, Pharmacology +14

(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways.

Isabelle Gorenne, Carlos Labat, Jean‐Pierre Gascard et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 29 citations

Medicine, Immunology, Pharmacology +15

Inversely-correlated inhibition of human 5-lipoxygenase activity by bay X1005 and other quinoline derivatives in intact cells and a cell-free system—implications for the function of 5-lipoxygenase activating protein

Armin Hatzelmann, J. Goossens, R. Fruchtmann et al. · Biochemical Pharmacology · 1994 · 25 citations

Life Sciences, Biochemistry, Pharmacology +13